ClinicalTrials.gg
CompletedNCT00141141Updated Feb 18, 2021

Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia

A Phase 4 interventional study of Atorvastatin and Simvastatin in Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 35 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
21st of 75
383 · median 148
Started
2004
with 2 others
Phase 4
28 of 77
1 open now
Registered
5th of 77
by date
Lead sponsor
10 of 77
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 21st largest by enrollment of the 75 interventional ones that give a count, is one of 3 that started in 2004, is one of 28 in phase 4, and was the 5th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of Atorvastin vs Simvastatin in decreasing LDL-C in diabetic subjects with hypercholesterolemia at the end of the treatment phase.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus
  • LDL-C > 130 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Insulin therapy
  • organ disease (creatininemia >2mg/dL, CHF III and IV)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
383 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the decrease of LDL-C after 24 weeks of treatment.

Secondary outcomes

  1. To evaluate the changes from baseline of targeted blood markers.

  2. To evaluate safety of Atorvastatin vs Simvastatin

07

Study locations

35 sites
  • Pfizer Investigational Site
    S. Benedetto DEL Tronto, Ascoli Piceno 63039, Italy
  • Pfizer Investigational Site
    S.Pietro Vernotico, Brindisi, Italy
  • Pfizer Investigational Site
    Casarano, Lecce 73043, Italy
  • Pfizer Investigational Site
    Pavia, PV 27100, Italy
  • Pfizer Investigational Site
    Orbassano, Torino 10043, Italy
  • Pfizer Investigational Site
    Mestre, VE 30174, Italy
  • Pfizer Investigational Site
    Ancona, 60100, Italy
  • Pfizer Investigational Site
    Asti, 14100, Italy
  • Pfizer Investigational Site
    Bari, 70124, Italy
  • Pfizer Investigational Site
    Cagliari, 09134, Italy
  • Pfizer Investigational Site
    Campobasso, 86100, Italy
  • Pfizer Investigational Site
    Catania, 95124, Italy
  • Pfizer Investigational Site
    Catania, 95126, Italy
  • Pfizer Investigational Site
    Catanzaro, 88100, Italy
  • Pfizer Investigational Site
    Ferrara, 44100, Italy
  • Pfizer Investigational Site
    Genova, 16132, Italy
  • Pfizer Investigational Site
    Messina, 98158, Italy
  • Pfizer Investigational Site
    Milano, 20142, Italy
  • Pfizer Investigational Site
    Milano, 20145, Italy
  • Pfizer Investigational Site
    Milano, 20157, Italy
  • Pfizer Investigational Site
    Napoli, 80100, Italy
  • Pfizer Investigational Site
    Napoli, 80131, Italy
  • Pfizer Investigational Site
    Palermo, 90127, Italy
  • Pfizer Investigational Site
    Parma, 43100, Italy
  • Pfizer Investigational Site
    Perugia, 06100, Italy
  • Pfizer Investigational Site
    Pisa, 56124, Italy
  • Pfizer Investigational Site
    Potenza, 85100, Italy
  • Pfizer Investigational Site
    Rimini, 47900, Italy
  • Pfizer Investigational Site
    Roma, 00155, Italy
  • Pfizer Investigational Site
    Roma, 00161, Italy
  • Pfizer Investigational Site
    Roma, 00163, Italy
  • Pfizer Investigational Site
    Roma, 00168, Italy
  • Pfizer Investigational Site
    S. Benedetto Del Tronto (AP), 63039, Italy
  • Pfizer Investigational Site
    Torino, 10154, Italy
  • Pfizer Investigational Site
    Udine, 33100, Italy
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Jan 2004
CompletionActual
Apr 2007
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00141141
Responsible party
Sponsor
First posted
Sep 1, 2005
Start date
Jan 2004
Completion
Apr 2007
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Simvastatin

Start the discussion